← FDA DRUG APPROVALS

FDA NDA · NDA020978

ZIAGEN

abacavir sulfate

Sponsor: VIIV HLTHCARE

APPLICATION
NDA020978
TYPE
NDA
ORIGINAL APPROVAL
1998-12-17
LATEST ACTION
2020-11-24
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ZIAGEN · ReferencePrescription
ABACAVIR SULFATE EQ 20MG BASE/ML · SOLUTION · ORAL

Approval history

2020-11-24Labeling · Supplement 38 · standardLabelAP
2018-05-09Labeling · Supplement 36 · standardLetterAP
2018-05-09Labeling · Supplement 37 · standardLetterAP
2017-03-20Labeling · Supplement 35 · standardLabelAP
2015-09-30Labeling · Supplement 34 · standardLetterAP
2015-03-23Efficacy · Supplement 31 · standardLabelAP
2015-02-19Labeling · Supplement 32 · standardLabelAP
2013-09-11Labeling · Supplement 30 · standardLabelAP
2012-05-18Labeling · Supplement 29 · standardLetterAP
2012-03-15Labeling · Supplement 28 · standardLetterAP
2011-11-18Labeling · Supplement 27 · 901 requiredLabelAP
2011-05-13REMS · Supplement 26LetterAP
2010-08-04REMS · Supplement 24LetterAP
2008-12-19Labeling · Supplement 22 · standardLetterAP
2008-07-18Efficacy · Supplement 20 · unknownLetterAP
2007-05-07Labeling · Supplement 19 · standardLetterAP
2006-08-11Labeling · Supplement 16 · standardLabelAP
2004-08-02Efficacy · Supplement 14 · unknownLetterAP
2004-07-26Labeling · Supplement 15 · standardLabelAP
2004-04-15Efficacy · Supplement 13 · unknownLetterAP
2003-07-17Labeling · Supplement 12 · standardLabelAP
2002-12-24Manufacturing (CMC) · Supplement 9 · priorityReviewAP
2002-10-02Labeling · Supplement 8 · standardLabelAP
2002-08-14Labeling · Supplement 10 · standardLetterAP
2002-06-04Labeling · Supplement 7 · standardAP
2002-01-28Labeling · Supplement 6 · standardLetterAP
2001-07-13Manufacturing (CMC) · Supplement 5 · priorityAP
2000-12-15Efficacy · Supplement 2 · standardReviewAP
2000-07-27Labeling · Supplement 4 · standardAP
2000-04-20Labeling · Supplement 1 · standardAP
1998-12-17Type 3 - New Dosage Form · Original · priorityReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →